早期类风湿关节炎不同DMARDs联合方案与糖皮质激素桥接治疗的两年疗效:CareRA研究
CareRA研究是一项为期两年的随机对照试验,纳入早期未使用过DMARDs和糖皮质激素的RA患者,按预后因素分层。高危组随机接受COBRA-Classic、COBRA-Slim或COBRA-Avant-Garde方案,低危组随机接受COBRA-Slim或TSU方案。结果显示所有含糖皮质激素的联合方案在2年内均有效,COBRA-Slim方案在疗效与安全性之间平衡最佳。
要点
- 高危组中COBRA-Slim的DAS28-CRP<2.6达标率与COBRA-Classic和COBRA-Avant-Garde相似(P=1.00)。
- COBRA-Slim治疗相关不良事件少于COBRA-Classic(P=0.02)和COBRA-Avant-Garde(P=0.005)。
- 低危组中COBRA-Slim与TSU的DAS28-CRP<2.6达标率相似(P=1.00),但COBRA-Slim纵向DAS28-CRP更低且需关节腔注射糖皮质激素更少。
核心结论
- 所有DMARDs联合糖皮质激素的方案对早期RA患者在2年内均有效。
- COBRA-Slim方案(MTX单药联合糖皮质激素桥接)在疗效与安全性之间提供最佳平衡,且不受患者预后影响。
研究设计与样本
- CareRA研究是一项为期两年的研究者发起的实用型多中心随机对照试验(NCT01172639)。
- 早期RA患者(未使用过DMARDs和糖皮质激素)按预后因素分层:高危组随机接受COBRA-Classic(n=98)、COBRA-Slim(n=98)或COBRA-Avant-Garde(n=93);低危组随机接受COBRA-Slim(n=43)或TSU(n=47)。
主要发现
- 高危组中,COBRA-Slim组71/98(72%)患者达到DAS28-CRP<2.6,COBRA-Classic组64/98(65%),COBRA-Avant-Garde组69/93(74%)(P=1.00)。
- 其他临床/影像学结局及缓解可持续性在各方案间相似。
- COBRA-Slim治疗相关不良事件少于COBRA-Classic(P=0.02)和COBRA-Avant-Garde(P=0.005)。
- 低危组中,COBRA-Slim组29/43(67%)和TSU组34/47(72%)达到DAS28-CRP<2.6(P=1.00)。
- 低危组中,COBRA-Slim患者2年内纵向DAS28-CRP评分更低,需关节腔注射糖皮质激素更少,安全性特征与TSU相当。
关键数值与推荐
- 高危组COBRA-Classic方案:MTX、柳氮磺吡啶、泼尼松从60 mg递减。
- 高危组COBRA-Slim方案:MTX、泼尼松从30 mg递减。
- 高危组COBRA-Avant-Garde方案:MTX、来氟米特、泼尼松从30 mg递减。
- 低危组TSU方案:MTX不加泼尼松。
临床怎么用
- 对于早期RA患者,可考虑MTX单药联合糖皮质激素桥接(COBRA-Slim方案)作为初始治疗,其疗效与更强化方案相当且安全性更优。
- 无论患者预后分层如何,COBRA-Slim方案均呈现较好的疗效与安全性平衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate whether MTX should be combined with an additional DMARD and bridging glucocorticoids as initial treatment for patients with early RA to induce an effective long-term response. METHODS: The Care in early RA study is a two-year investigator-initiated pragmatic multicentre randomized trial. Early RA patients, naïve to DMARDs and glucocorticoids, were stratified based on prognostic factors. High-risk patients were randomized to COBRA-Classic (n = 98): MTX, sulfasalazine, prednisone step-down from 60 mg; COBRA-Slim (n = 98): MTX, prednisone step-down from 30 mg; or COBRA-Avant-Garde (n = 93): MTX, leflunomide, prednisone step-down from 30 mg. Low-risk patients were randomized to COBRA-Slim (n = 43); or Tight Step Up (TSU) (n = 47): MTX without prednisone. Clinical/radiological outcomes at year 2, sustainability of response, safety and treatment adaptations were assessed. RESULTS: In the high-risk group 71/98 (72%) patients achieved a DAS28-CRP < 2.6 with COBRA-Slim compared with 64/98 (65%) with COBRA-Classic and 69/93 (74%) with COBRA-Avant-Garde (P = 1.00). Other clinical/radiological outcomes and sustainability of response were similar. COBRA-Slim treatment resulted in less therapy-related adverse events compared with COBRA-Classic (P = 0.02) or COBRA-Avant-Garde (P = 0.005). In the low-risk group, 29/43 (67%) patients on COBRA-Slim and 34/47 (72%) on TSU achieved a DAS28-CRP < 2.6 (P = 1.00). On COBRA-Slim, low-risk patients had lower longitudinal DAS28-CRP scores over 2 years, a lower need for glucocorticoid injections and a comparable safety profile compared with TSU. CONCLUSION: All regimens combining DMARDs with glucocorticoids were effective for patients with early RA up to 2 years. The COBRA-Slim regimen, MTX monotherapy with glucocorticoid bridging, provided the best balance between efficacy and safety, irrespective of patients' prognosis. TRIAL REGISTRATION: ClinicalTrials.gov, http://www.clinicaltrials.gov, NCT01172639.
引用
- Stouten V, Westhovens R, Pazmino S, et al. Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA. Rheumatology (Oxford). 2019. PMID: 31236568. doi:10.1093/rheumatology/kez213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。